Trading Halt
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Dimerix Limited has requested a trading halt for its securities pending an announcement regarding a licensing agreement. The halt will remain in effect until the earlier of the commencement of normal trading on a specified date or the announcement's release. This request has been authorized by the Board of Dimerix Limited.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/trading-halt-321
In the deck
Earlier from Dimerix
- FDA confirms Proteinuria as Primary Endpoint for US approval
- S&P DJI Announces March 2025 Quarterly Rebalance
- Dimerix receives initial upfront payment from FUSO
- Half-Year Financial Report & Appendix 4D - 31 December 2024
- First Paediatric Patient Recruited for ACTION3
Later from Dimerix
- Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
- Dimerix Licenses DMX-200 in the US
- Investor Webinar and Presentation
- Dimerix receives initial upfront payment from Amicus
- Successful planned IDMC review of ACTION3 trial
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix